Bavarian Nordic A/S

ISIN DK0015998017

 | 

WKN 917165

Market cap (in EUR)
2,022 m
Country
Denmark
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Denmark

Financials

Key metrics

Market capitalisation, EUR 2,022 m
EPS, EUR 4.19
P/B ratio 1.1
P/E ratio 6.1
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 766 m
Net income, EUR 132 m
Profit margin 17.30%

What ETF is Bavarian Nordic A/S in?

There are 3 ETFs which contain Bavarian Nordic A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Bavarian Nordic A/S is the iShares STOXX Europe 600 Health Care UCITS ETF (DE).
ETF Weight Investment focus Fund size (in m EUR)
Vanguard ESG Developed Europe All Cap UCITS ETF (EUR) Distributing 0.03%
Equity
Europe
Social/Environmental
31
iShares STOXX Europe 600 Health Care UCITS ETF (DE) 0.16%
Equity
Europe
Health Care
707
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
485
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.